ASCO 2020：11项中国学术研究入选口头报告，17项Poster报告

受全球新冠疫情严重影响，原定于5月末29日~6月末2日在芝加哥召开的新泽西州临床学都会（ASCO）年都会上周将首次以线上形式举办地，这是目前最大规模的线上盛都会。现在，都大会的简要出题公布，共103个sessions，中都会国共有11项深入研究被选为口头报告，17项被选为Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或卡马替尼加卡培他滨用于HER2+结核乳腺肿疣（PHOEBE）：一项III期随机试验车。

第二场：结核乳腺肿疣

写作者：中都会国医学科学院公立医院徐兵河客座教授、马飞客座教授，复旦大学附属公立医院胡夕春客座教授等

简要号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴官能乳腺肿疣标准规范治疗法后卡培他滨保持鼓点抗生素的III期试验车（SYSUCC-001）。

第二场：乳腺肿疣—角化/范围内/基本功能治疗法

写作者：中都会山大学防治中都会心王树森客座教授等

简要号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用结核脊髓的表现型特征来预期脊髓脊液中都会循环DNA测定的概率: 新工具压制老对手

第二场：新工具化解老难题

写作者：李美芹 李德兰等

简要号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

塔纳非尼对奈及利亚拉非尼作为后半期大肠线粒体肿疣的三线治疗法：一项新开字句、随机、多中都会心II/III期试验车。

第二场：消化道肠道肿疣—消化道输尿管、坏死和自是

写作者：西安交通大学宝兴公立医院毕锋客座教授、中都会国民众解放军八一公立医院秦叔逵客座教授等

简要号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

中都会国后半期大肠肿疣病患阿帕替尼二线治疗法：一项随机、安慰剂折衷、双盲III期深入研究

第二场：消化道肠道肿疣—消化道输尿管、坏死和自是

写作者：中都会国民众解放军八一公立医院秦叔逵客座教授、西安交通大学宝兴公立医院李秋客座教授等

简要号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

后半期膀胱肿疣卵巢肿疣二次线粒体减灭术的一项随机III期试验车：SOC1 / SGOG-OV2。

研讨：护理人员前列腺癌

写作者：复旦大学附属中都会山公立医院臧荣余客座教授等

简要：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈肿疣根治官能输卵管输精管后基本功能治疗法中都会的序贯放抗生素对比单独化学疗法或同步放抗生素（STARS深入研究）：一项随机、折衷、新开字句的III期试验车。

都大会：护理人员前列腺癌

写作者：中都会山大学防治中都会心黄鹤客座教授、刘继红客座教授等

简要号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：基本功能吉非替尼对比抗生素用于可切除的EGFR基因的N1-N2期NSCLC-随机III期临床实验的最终总体求生深入研究。

研讨：心肌梗塞—非小线粒体角化-范围内/小线粒体/其他胸部

写作者：惠州市民众公立医院吴一龙客座教授等

简要号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR基因寡移转到非小线粒体心肌梗塞病患三线过氧化物还原酶药物重新组建或不重新组建积极前线角化化学疗法：III期新开字句临床随机试验车（SINDAS）的中都会期结果（NCT02893332）。

研讨：心肌梗塞-非小线粒体移转到

写作者：四川省民众公立医院曾铭客座教授等

简要：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序官能遇害-1（PD-1）的人源化IgG4化学合成重新组建阿昔替尼用于结核黏膜皮肤肿疣病患的Ib期深入研究的总求生期和生物体标志物深入研究。

研讨：皮肤肿疣/皮肤肿疣

写作者：北京大学公立医院郭军、盛锡楠客座教授等

简要：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的安全官能和结果：通用CAR-T线粒体首次人体试验车治疗法中风/难治官能T线粒体急官能淋巴线粒体前列腺癌（r/r T-ALL）的安全官能和。都大会：研发中都会的治疗法技术-免疫治疗法。写作者：王欣欣等简要：3013的广告：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在后半期输尿管鳞状线粒体肿疣病患中都会的领域：一项随机的新开字句II期试验车（ORIENT-2）。都大会：消化道肠道肿疣-消化道输尿管肿疣、坏死肿疣和自是道肿疣写作者：徐建明客座教授等简要：4511的广告：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异官能CAR-T线粒体对髓母线粒体疣的根除官能治疗法都大会：中都会枢神经系统写作者：代红久、孙斌、杨东、徐晖、徐晶晶、魏佳、陈旭东简要：2522的广告。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在后半期错配修复缺陷病患中都会的领域都大会：研发中都会的治疗法学-免疫治疗法写作者：沈琳客座教授等简要：3021的广告。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 免疫CD7-CART治疗法中风/难治官能ACUTE淋巴线粒体前列腺癌/肉疣的首例人体临床实验都大会: 研发官能治疗法学-免疫治疗法写作者简介：张明志，杨林等简要：3026的广告: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 阿伦替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）重新组建领域领域后半期实体疣病患的Ib期深入研究都大会：发展官能治疗法学--分子会抗病毒药物和生物体学写作者：龚继芳，沈琳客座教授等简要：3523的广告：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin重新组建紫杉醇和nedaplatin治疗法膀胱肿疣或结核输尿管鳞状线粒体肿疣（ESCC）病患的II期深入研究。都大会：消化道肠道肿疣-消化道输尿管、坏死和自是道肿疣的深入研究写作者：王志过关斩将，李玉红，王德申，王凤华，任超，谭琼 王志过关斩将、李玉红、王德深、王凤华、任超、谭琼简要：4522的广告：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.都大会：消化道肠道肿疣-消化道输尿管肿疣、坏死肿疣和自是管肿疣的二线治疗法写作者：宋艳等简要：4524的广告：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿液外体外侧RNA线官能系统用于初始活检时测定高等级肿疣的尿液外体外侧RNA线官能系统：一项多中都会心的回顾官能深入研究都大会：泌尿循环系统前列腺癌---肿疣、中风和肿疣写作者简介：Liaoyuan Li等简要：5522的广告。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 角化后半期宫颈肿疣并发抗生素后的基本功能抗生素都大会: 护理人员前列腺癌写作者简介： 李珉珉等简要：6031的广告：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼治疗法大肠脏髓官能肿疣的相关官能：基于ALTER01031试验车的深入研究。都会话：黑纹写作者：天津市公立医院高明客座教授简要：6526的广告。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年龄对安洛替尼治疗法后病患剧情的严重影响: ALTER01031的亚组深入研究都大会：黑纹写作者：天津市公立医院高明客座教授简要：6527的广告。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA深入研究预期I-IIIA期非小线粒体心肌梗塞（NSCLC）病患术后中风: GASTO1035和GASTO1018的结果都大会：心肌梗塞-非小线粒体角化-范围内官能/小线粒体/小线粒体/其他胸科前列腺癌写作者：Si-Yu Wang等简要：9023的广告：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小线粒体心肌梗塞（NSCLC）中都会EGFR过氧化物还原酶药物的新型耐药机制都大会:心肌梗塞-非小线粒体结核心肌梗塞写作者简介：陈昕，金艾利，满宇，欧名妓，华宝，薛武，杨少，范敏 陈昕、金艾利、满宇、欧名妓、华宝、薛武、杨绍、范敏简要：9528的广告：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1试验车中都会后半期皮肤肿疣总求生的替代往北都大会：皮肤肿疣/皮肤肿疣写作者：聂润聪，袁书过关斩将，李元芳，陈英波，周志伟 聂润聪、袁书过关斩将、李元芳、陈英波、周志伟简要：10030的广告：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼治疗法中风或结核病症恶官能穿孔病患的II期深入研究都大会： 溃疡写作者：唐丽娜，牛晓辉，王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王振、蔡启庆、涂崇奇、范正福、杨瑶简要：11525的广告。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步评价安罗替尼在后半期溃疡病患多线治疗法中都会的安全官能和。都大会：溃疡写作者：姚伟涛，黄家过关斩将，玑，王欣，杜新辉，田志浩，牛晓颖 姚伟涛、黄家过关斩将、玑、王鑫、杜鑫辉、田志超、牛晓英简要：11526的广告：414